Last 12 months
Inside the activity.
1 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 8 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 0 |
| Jun 2026 | 1 | 3 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC |
NODELMAN OLEGDirector · 10% owner
EcoR1 Panacea Holdings, LLC10% owner
EcoR1 Capital Fund, L.P.10% owner
EcoR1 Capital Fund Qualified, L.P.10% owner
EcoR1 Venture Opportunity Fund, LP10% owner
EcoR1 Capital, LLC10% owner
Biotech Opportunity GP, LLC10% owner
|
GrantClass A Common Stock | 394,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 394,000 F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC |
NODELMAN OLEGDirector · 10% owner
EcoR1 Panacea Holdings, LLC10% owner
EcoR1 Capital Fund, L.P.10% owner
EcoR1 Capital Fund Qualified, L.P.10% owner
EcoR1 Venture Opportunity Fund, LP10% owner
EcoR1 Capital, LLC10% owner
Biotech Opportunity GP, LLC10% owner
|
GrantClass A Common Stock | 2,106,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 2,106,000 F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F4 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC |
NODELMAN OLEGDirector · 10% owner
EcoR1 Panacea Holdings, LLC10% owner
EcoR1 Capital Fund, L.P.10% owner
EcoR1 Capital Fund Qualified, L.P.10% owner
EcoR1 Venture Opportunity Fund, LP10% owner
EcoR1 Capital, LLC10% owner
Biotech Opportunity GP, LLC10% owner
|
ConversionClass A Common Stock | 2,775,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Liability Company Disclosed balance after: 3,165,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F2 · ownership.nature: EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC but each (other than EcoR1 Panacea Holdings, LLC) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:59 UTC |
Omega Fund V, L.P.10% owner
Omega Fund V GP, L.P.10% owner
Omega Fund V GP Manager, Ltd.10% owner
Stampacchia Otello10% owner
Nessi Claudio10% owner
Paster Anne-Mari10% owner
DOIG MICHELLEDirector
|
ConversionSeries A Preferred Stock · Derivative | 8,130,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010367 · doc4.xml · derivative · entry 3 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner DOIG MICHELLE · CIK 0001832320 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 8,130,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). The transactions contemplated by the Merger Agreement are referred to herein as the "Business Combination." F5 · kind: Each share of Series A Preferred Stock stock automatically converted into Class A Common Stock on a 1-for-1 basis immediately prior to the closing of the Business Combination and has no expiration date nor conversion price. F1 · derivative.exercise_date: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). The transactions contemplated by the Merger Agreement are referred to herein as the "Business Combination." F1 · derivative.expiration_date: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). The transactions contemplated by the Merger Agreement are referred to herein as the "Business Combination." Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:59 UTC |
Omega Fund V, L.P.10% owner
Omega Fund V GP, L.P.10% owner
Omega Fund V GP Manager, Ltd.10% owner
Stampacchia Otello10% owner
Nessi Claudio10% owner
Paster Anne-Mari10% owner
DOIG MICHELLEDirector
|
GrantClass A Common Stock | 500,000 | $10.00 | $5,000,000.00 |
DisclosureSEC source: 0001209191-21-010367 · doc4.xml · nonDerivative · entry 2 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner DOIG MICHELLE · CIK 0001832320 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,212,373 F4 · shares: On October 20, 2020, the Issuer entered into subscription agreements (the "Subscription Agreements") with certain investors (the "PIPE Investors") pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, as defined herein, an aggregate of $476,550,000 of the Issuer's shares of Class A Common Stock at a price of $10.00 per share, or an aggregate of 47,655,000 shares of Class A Common Stock. The Reporting Person is among the PIPE Investors. F3 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Michelle Doig is a partner of Omega V and shares voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager, the Omega Directors and Michelle Doig disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:59 UTC |
Omega Fund V, L.P.10% owner
Omega Fund V GP, L.P.10% owner
Omega Fund V GP Manager, Ltd.10% owner
Stampacchia Otello10% owner
Nessi Claudio10% owner
Paster Anne-Mari10% owner
DOIG MICHELLEDirector
|
ConversionClass A Common Stock | 8,130,097 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-010367 · doc4.xml · nonDerivative · entry 1 Omega Fund V, L.P. · CIK 0001641354 · 10% owner Omega Fund V GP, L.P. · CIK 0001641355 · 10% owner Omega Fund V GP Manager, Ltd. · CIK 0001641348 · 10% owner Stampacchia Otello · CIK 0001361712 · 10% owner Nessi Claudio · CIK 0001722050 · 10% owner Paster Anne-Mari · CIK 0001652863 · 10% owner DOIG MICHELLE · CIK 0001832320 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,712,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). The transactions contemplated by the Merger Agreement are referred to herein as the "Business Combination." F2 · balance_after: Includes 19,582,276 shares issued in connection with the conversion of shares of Class A Common Stock in the Business Combination, as defined herein. F3 · ownership.direct: The reported securities are held directly by Omega Fund V, L.P. ("Omega V"). The reported securities may be deemed to be beneficially owned by each of Omega Fund V GP, L.P. ("Omega V GP"), as the general partner of Omega V, and Omega Fund V GP Manager, Ltd. ("Omega V GP Manager"), as the general partner of Omega V GP. Otello Stampacchia, Anne-Mari Paster and Claudio Nessi (the "Omega Directors") are all the shareholders and directors of Omega V GP Manager and have shared voting and investment power over the shares held by Omega V. Michelle Doig is a partner of Omega V and shares voting and investment power over the shares held by Omega V. Each of Omega V GP, Omega Fund V GP Manager, the Omega Directors and Michelle Doig disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:56 UTC |
VERNON W ANTHONYDirector
|
GrantStock Option (Right to Buy) · Derivative | 187,658 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010362 · doc4.xml · derivative · entry 4 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,658 Underlying: Class A Common Stock · 187,658 shares Expires 2030-01-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F6 · price: Received in exchange for an option to purchase 187,658 shares of Legacy Nuvation Class A Common Stock. F5 · derivative.exercise_date: Options vest in 48 equal monthly installments from July 17, 2019. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:56 UTC |
VERNON W ANTHONYDirector
|
GrantStock Option (Right to Buy) · Derivative | 51,703 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010362 · doc4.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,703 Underlying: Class A Common Stock · 51,703 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F4 · price: Received in exchange for an option to purchase 51,703 shares of Legacy Nuvation Class A Common Stock. F3 · derivative.exercise_date: Options vest in 48 equal monthly installments from October 5, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:55 UTC |
FALBERG KATHRYN EDirector
|
GrantStock Option (Right to Buy) · Derivative | 239,361 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010360 · doc4.xml · derivative · entry 1 FALBERG KATHRYN E · CIK 0001206977 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,361 Underlying: Class A Common Stock · 239,361 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 239,022 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest in 48 equal monthly installments from October 12, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:54 UTC |
BLICKENSTAFF KIM DDirector
|
GrantStock Option (Right to Buy) · Derivative | 187,658 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010356 · doc4.xml · derivative · entry 2 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,658 Underlying: Class A Common Stock · 187,658 shares Expires 2030-01-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F5 · price: Received in exchange for an option to purchase 187,392 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest in 48 equal monthly installments from August 27, 2019. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:54 UTC |
BLICKENSTAFF KIM DDirector
|
GrantStock Option (Right to Buy) · Derivative | 51,703 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010356 · doc4.xml · derivative · entry 1 BLICKENSTAFF KIM D · CIK 0001238913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,703 Underlying: Class A Common Stock · 51,703 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 51,630 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest in 48 equal monthly installments from October 5, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:53 UTC |
Bazemore Robert BDirector
|
GrantStock Option (Right to Buy) · Derivative | 187,658 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010354 · doc4.xml · derivative · entry 2 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,658 Underlying: Class A Common Stock · 187,658 shares Expires 2030-07-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F5 · price: Received in exchange for an option to purchase 187,392 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest in 48 equal monthly installments from July 22, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:53 UTC |
Bazemore Robert BDirector
|
GrantStock Option (Right to Buy) · Derivative | 51,703 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010354 · doc4.xml · derivative · entry 1 Bazemore Robert B · CIK 0001620152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,703 Underlying: Class A Common Stock · 51,703 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 51,630 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest in 48 equal monthly installments from October 5, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:51 UTC |
WELCH DANIEL GDirector
|
GrantStock Option (Right to Buy) · Derivative | 312,750 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010347 · doc4.xml · derivative · entry 2 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,750 Underlying: Class A Common Stock · 312,750 shares Expires 2030-07-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F5 · price: Received in exchange for an option to purchase 312,307 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest in 48 equal monthly installments from July 22, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:51 UTC |
WELCH DANIEL GDirector
|
GrantStock Option (Right to Buy) · Derivative | 86,184 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010347 · doc4.xml · derivative · entry 1 WELCH DANIEL G · CIK 0001206199 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,184 Underlying: Class A Common Stock · 86,184 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 86,603 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest in 48 equal monthly installments from October 5, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:48 UTC |
Templeman ThomasSVP, Pharmaceutical Ops
|
GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010339 · doc4.xml · derivative · entry 2 Templeman Thomas · CIK 0001654274 · SVP, Pharmaceutical Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-01-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest as to 25% on July 1, 2020 and in equal monthly installments thereafter over the following three years. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:48 UTC |
Templeman ThomasSVP, Pharmaceutical Ops
|
GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010339 · doc4.xml · derivative · entry 1 Templeman Thomas · CIK 0001654274 · SVP, Pharmaceutical Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:50 UTC |
Markel StacySVP, Human Resources
|
GrantStock Option (Right to Buy) · Derivative | 254,810 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010344 · doc4.xml · derivative · entry 2 Markel Stacy · CIK 0001734780 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,810 Underlying: Class A Common Stock · 254,810 shares Expires 2030-01-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F5 · price: Received in exchange for an option to purchase 254,810 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest as to 25% on September 30, 2020 and in equal monthly installments thereafter over the following three years. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:50 UTC |
Markel StacySVP, Human Resources
|
GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010344 · doc4.xml · derivative · entry 1 Markel Stacy · CIK 0001734780 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:47 UTC |
Hattersley GaryChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010334 · doc4.xml · derivative · entry 2 Hattersley Gary · CIK 0001521111 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-01-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest as to 25% on July 1, 2020 and in equal monthly installments thereafter over the following three years. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:47 UTC |
Hattersley GaryChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010334 · doc4.xml · derivative · entry 1 Hattersley Gary · CIK 0001521111 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:46 UTC |
Yurasov SergeyChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010332 · doc4.xml · derivative · entry 2 Yurasov Sergey · CIK 0001686295 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-01-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest as to 25% on September 17, 2020 and in equal monthly installments thereafter over the following three years. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:46 UTC |
Yurasov SergeyChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010332 · doc4.xml · derivative · entry 1 Yurasov Sergey · CIK 0001686295 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:46 UTC |
Fox Jennifer A.Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 558,506 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010330 · doc4.xml · derivative · entry 2 Fox Jennifer A. · CIK 0001841557 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,506 Underlying: Class A Common Stock · 558,506 shares Expires 2030-10-11 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F5 · price: Received in exchange for an option to purchase 558,506 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest as to 20% on October 12, 2023, 20% on October 12, 2024 and 60% on October 12, 2025, subject to achievement of performance criteria. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:46 UTC |
Fox Jennifer A.Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010330 · doc4.xml · derivative · entry 1 Fox Jennifer A. · CIK 0001841557 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-10-11 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest as to 25% on October 12, 2021 and in equal monthly installments thereafter over the following three years. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:45 UTC |
Hung DavidDirector · President and CEO · 10% owner
|
GrantClass B Common Stock · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010326 · doc4.xml · derivative · entry 3 Hung David · CIK 0001310880 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Class A Common Stock · 1,000,000 shares Expires not disclosed F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon the earliest of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's amended and restated certificate of incorporation, (ii) the death of the Reporting Person in the case of shares held directly or in a trustee capacity, and (iii) the tenth anniversary of the Issuer's initial public offering of its Class A Common Stock. F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon the earliest of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's amended and restated certificate of incorporation, (ii) the death of the Reporting Person in the case of shares held directly or in a trustee capacity, and (iii) the tenth anniversary of the Issuer's initial public offering of its Class A Common Stock. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon the earliest of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's amended and restated certificate of incorporation, (ii) the death of the Reporting Person in the case of shares held directly or in a trustee capacity, and (iii) the tenth anniversary of the Issuer's initial public offering of its Class A Common Stock. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:45 UTC |
Hung DavidDirector · President and CEO · 10% owner
|
GrantClass A Common Stock | 2,000,000 | $10.00 | $20,000,000.00 |
DisclosureSEC source: 0001209191-21-010326 · doc4.xml · nonDerivative · entry 2 Hung David · CIK 0001310880 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,645,012 F2 · shares: On October 20, 2020, the Issuer entered into subscription agreements (the "Subscription Agreements") with certain investors (the "PIPE Investors") pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, as defined herein, an aggregate of $476,550,000 of the Issuer's shares of Class A Common Stock at a price of $10.00 per share, or an aggregate of 47,655,000 shares of Class A Common Stock. The Reporting Person is among the PIPE Investors. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:45 UTC |
Hung DavidDirector · President and CEO · 10% owner
|
GrantClass A Common Stock | 56,645,012 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-010326 · doc4.xml · nonDerivative · entry 1 Hung David · CIK 0001310880 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,645,012 F1 · price: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). Read SEC document |
| February 10, 2021 Filed Feb 27, 2021 00:02 UTC |
Sharp ShaliniDirector
|
Exercise / conversionClass B Common Stock · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-012235 · ownership.xml · derivative · entry 3 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.exercise_date: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Read SEC document |
| February 10, 2021 Filed Feb 27, 2021 00:02 UTC |
Sharp ShaliniDirector
|
GrantClass A Common Stock | 10,000 | $10.00 | $100,000.00 |
DisclosureSEC source: 0001213900-21-012235 · ownership.xml · nonDerivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F2 · price: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share. Read SEC document |
| February 10, 2021 Filed Feb 27, 2021 00:02 UTC |
Sharp ShaliniDirector
|
Exercise / conversionClass A Common Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-012235 · ownership.xml · nonDerivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Read SEC document |
| February 10, 2021 Filed Feb 27, 2021 00:01 UTC |
BRADBURY DANIELDirector
|
Exercise / conversionClass B Common Stock · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-012233 · ownership.xml · derivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.exercise_date: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Read SEC document |
| February 10, 2021 Filed Feb 27, 2021 00:01 UTC |
BRADBURY DANIELDirector
|
Exercise / conversionClass A Common Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-012233 · ownership.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Read SEC document |
| February 10, 2021 Filed Feb 27, 2021 00:00 UTC |
Hasnain FaheemDirector
|
Exercise / conversionClass B Common Stock · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-012230 · ownership.xml · derivative · entry 3 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.exercise_date: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Read SEC document |
| February 10, 2021 Filed Feb 27, 2021 00:00 UTC |
Hasnain FaheemDirector
|
GrantClass A Common Stock | 30,000 | $10.00 | $300,000.00 |
DisclosureSEC source: 0001213900-21-012230 · ownership.xml · nonDerivative · entry 2 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F2 · price: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share. Read SEC document |
| February 10, 2021 Filed Feb 27, 2021 00:00 UTC |
Hasnain FaheemDirector
|
Exercise / conversionClass A Common Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-012230 · ownership.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Read SEC document |
| February 10, 2021 Filed Feb 26, 2021 23:59 UTC |
COOPER GRAHAM KDirector
|
Exercise / conversionClass B Common Stock · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-012228 · ownership.xml · derivative · entry 2 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.exercise_date: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Read SEC document |
| February 10, 2021 Filed Feb 26, 2021 23:59 UTC |
COOPER GRAHAM KDirector
|
Exercise / conversionClass A Common Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-012228 · ownership.xml · nonDerivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. Read SEC document |
| July 06, 2020 Filed Jul 6, 2020 17:06 UTC |
EcoR1 Panacea Holdings, LLCDirector · 10% owner
NODELMAN OLEGDirector · CEO and Chairman of the Board
EcoR1 Capital Fund, L.P.Director · 10% owner
EcoR1 Capital Fund Qualified, L.P.Director · 10% owner
EcoR1 Venture Opportunity Fund, LPDirector · 10% owner
EcoR1 Capital, LLCDirector · 10% owner
Biotech Opportunity GP, LLCDirector · 10% owner
|
PurchaseClass A common stock | 390,000 | $10.00 | $3,900,000.00 |
DisclosureSEC source: 0001213900-20-016762 · ownership.xml · nonDerivative · entry 1 EcoR1 Panacea Holdings, LLC · CIK 0001816134 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · CEO and Chairman of the Board EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 F1 · shares: The reported shares are included within the 390,000 private placement units of the issuer purchased by EcoR1 Panacea Holdings, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the issuer's initial public offering, and each such unit consists of one share of Class A common stock of the issuer and one-third of one redeemable warrant of the issuer. The warrants included in the units will become exercisable, if at all, on the later of 30 days after the completion of the issuer's initial business combination and 12 months from the closing of the issuer' initial public offering. F2 · ownership.direct: The reporting owner, the Sponsor, in whose name the securities reported herein are held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document |
| February 10, 2020 Filed Feb 12, 2021 22:56 UTC |
VERNON W ANTHONYDirector
|
GrantClass A Common Stock | 50,000 | $10.00 | $500,000.00 |
DisclosureSEC source: 0001209191-21-010362 · doc4.xml · nonDerivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,100 F2 · shares: On October 20, 2020, the Issuer entered into subscription agreements (the "Subscription Agreements") with certain investors (the "PIPE Investors") pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, as defined herein, an aggregate of $476,550,000 of the Issuer's shares of Class A Common Stock at a price of $10.00 per share, or an aggregate of 47,655,000 shares of Class A Common Stock. The Reporting Person is among the PIPE Investors. Read SEC document |
| February 10, 2020 Filed Feb 12, 2021 22:56 UTC |
VERNON W ANTHONYDirector
|
GrantClass A Common Stock | 254,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-010362 · doc4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,100 F1 · price: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.